Pharmaceutical composition for intraocular or oral administration for treatment of retinal diseases

A technology for retinal diseases and intraocular drug delivery, which can be used in drug combinations, sensory diseases, drug delivery, etc., and can solve problems such as low doses

Pending Publication Date: 2021-08-20
FUSO PHARMA INDS +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, there are also public cases of administration based on local route or oral administration, but the dosage (dose) is not low

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for intraocular or oral administration for treatment of retinal diseases
  • Pharmaceutical composition for intraocular or oral administration for treatment of retinal diseases
  • Pharmaceutical composition for intraocular or oral administration for treatment of retinal diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0196] Although formulation examples and test examples are given below and this invention is demonstrated more concretely, this invention is not limited to these examples.

[0197] Compounds, mice, reagents, etc. used in Examples are commercially available or produced according to known methods.

[0198] Preparation example

[0199] Formulation examples of the pharmaceutical composition of the present invention are shown below, but are not limited thereto.

preparation example 1

[0201] tablet

[0202] [Table 1]

[0203]

[0204] Tablets are manufactured in accordance with a generally known method for tablet formulation. Specifically, mix methyldopa, cornstarch and lactose as the present compound in a mixer, add carboxymethylcellulose calcium and hydroxypropyl cellulose to the mixture for granulation, dry the obtained granules and then granulate granules, magnesium stearate is added to the sized granules for mixing, and the tablets are compressed using a tablet machine. In addition, by changing the amount of the present compound added, tablets with a desired content (for example, 10 mg, 25 mg, or 50 mg) in 100 mg tablets can be produced.

preparation example 2

[0206] eye drops

[0207] [Table 2]

[0208]

[0209]

[0210] Eye drops are produced according to a generally known method for formulating eye drops. Specifically, eye drops were prepared by adding methyldopa as the present compound and the other above-mentioned components to sterilized purified water and mixing them well. By changing the addition amount of this compound such as methyldopa, the desired concentration (for example, 0.3% (W / V), 0.5% (W / V) or 1% (W / V) in 100mL of eye drops can be manufactured. )) eye drops.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to view more

Abstract

The present invention provides: a pharmaceutical composition that is to be intraocularly or orally administered for preventing or treating a retinal disease (e.g., age-related macular degeneration) of a patient who needs to be treated, or inhibiting the progression of the disease, and that contains a pharmaceutically-acceptable carrier and an effective amount of at least one compound selected from the group consisting of apomorphine, eseroline, ethoxyquin, methyldopa, olanzapine, indapamide, and the like; and a method.

Description

technical field [0001] The present invention provides intraocular or oral medicaments and methods for preventing or treating retinal diseases (for example, age-related macular degeneration), or for inhibiting the progression of the diseases. Background technique [0002] Retinal diseases, including retinitis pigmentosa and age-related macular degeneration, have mostly unknown causes and are difficult to treat. Human beings obtain external information through the five senses including vision, and in particular, more than 80% of information is obtained through vision. Therefore, visual impairment caused by difficult-to-treat retinal diseases can significantly reduce the patient's quality of life (QOL). [0003] It is well known that age-related macular degeneration (AMD) is a disease with low treatment satisfaction and drug contribution to treatment and high unmet medical needs (Unmet Medical Needs). According to the pathogenesis, age-related macular degeneration can be roug...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/137A61K31/403A61K31/407A61K31/47A61P27/02A61K9/06A61K9/08A61K9/20
CPCA61K31/407A61P27/02A61K9/06A61K9/0048A61K9/4841A61K9/1605A61K9/0095A61K9/10A61K9/2059A61K9/2018A61K9/2054A61K9/2077A61K47/06A61K31/473A61K31/198A61K31/551A61K31/404A61K31/47A61K31/245A61K31/4439A61K31/4045A61K31/137A61K45/06
Inventor 山田健一进藤早纪石田南人山本启一
Owner FUSO PHARMA INDS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap